No hype, just logic. Low market cap in relationship to others in the space. Major fund 4.4 million shares-same company owns large position in Puma, a stock that went from the 20'3 to over 200.00. Major collaborative agreements and several, not one or two or three drug applications. Stock should trend into the teens.